|
inhalation-human TCAs- mg/m3/11Y-I: Carcinogenic effects, BLD BJIMAG
<br /> -44, 124, 87
<br /> inhalation-mouse TC:300 ppm/6H/16W-I: Carcinogenic effects IMMUAM
<br /> (3) , 156, 84
<br /> inhalation-human LCLo:2 pph/5M TABIA2 3,231, 33
<br /> oral-man LDLo:50 mg/kg YAKUD5 22, 883, 80
<br /> inhalation-human LCLo:20000 ppm/5M 29ZUA8 -, -, 53
<br /> inhalation-man TCLo:150 ppm/lY-I: Blood effects BLUTA9 28, 293, 74
<br /> inhalation-human TCLo:100 ppm INMEAF 17, 199, 48
<br /> inhalation-human LCLo: 65 mg/m3/5Y: Blood effects ARGEAR 44, 145, 74
<br /> oral-rat LD50 :3306 mg/kg TXAPA99 19, 699, 71
<br /> inhalation-rat LC50 : 10000 ppm/7H 28ZRAQ -, 113, 60
<br /> intraperitoneal-rat LD50 :2890 mg/kg 36YFAG -, 302, 77
<br /> oral-mouse LD50 :4700 mg/kg HYSAAV 32, 349, 67
<br /> inhalation-mouse LC50 : 9980 ppm JIHTAB 25, 366, 43
<br /> intraperitoneal-mouse LD50:340 mg/kg ANYAA9 243, 104, 75
<br /> oral-dog, adult LDLo:2000 mg/kg HBAMAK 4, 1313, 35
<br /> inhalation-dog, adult LCLo: 146000 mg/m3 HBTXAC 1, 324, 56
<br /> inhalation-cat, adult LCLo: 170000 mg/m3 HBTXAC 1, 324, 56
<br /> intravenous-rabbit, adult LDLo: 88 mg/kg JTEHD6 - (Suppl.2) , 45, 77
<br /> Consensus Reports:
<br /> NTP Fifth Annual Report on Carcinogens. IARC Cancer Review: Group 1
<br /> IMEMDT 7, 120, 87, Human Limited Evidence IMEMDT 7, 203, 74; Animal
<br /> Inadequate Evidence IMEMDT 7, 203, 74; IARC Cancer Review: Animal Limited
<br /> Evidence IMEMDT 29, 93, 82; Human Sufficient Evidence IMEMDT 29, 93, 82. NTP
<br /> Carcinogenesis Studies (gavage) ; Clear Evidence: mouse, rat NTPTR* NTP-
<br /> TR-289, 86. EPA Genetic Toxicology Program. Reported in EPA TSCA
<br /> Inventory. On Community Right-To-Know List.
<br /> Standards and Recommendations:
<br /> OSHA PEL: TWA 1 ppm; STEL 5 ppm; Pk 5 ppm/15M/8H; Cancer Hazard
<br /> ACGIH TLV: TWA 10 ppm; Suspected Human Carcinogen (Proposed: TWA 0. 1
<br /> ppm; Confirmed Human Carcinogen) ; BEI: 50 mg(total phenol) /L in urine at
<br /> end of shift recommended as a mean value.
<br /> DFG TRK:5 ppm (16 mg/m3) Human Carcinogen.
<br /> NIOSH REL: TWA 0.32 mg/m3; CL 3.2 mg/m3/15M
<br /> DOT Classification: 3; Label: Flammable Liquid
<br /> SAFETY PROFILE:
<br /> Confirmed human carcinogen producing myeloid leukemia, Hodgkin's
<br /> disease, and lymphomas by inhalation. Experimental carcinogenic,
<br /> neoplastigenic, and tumorigenic data. A human poison by inhalation. An
<br /> experimental poison by skin contact, intraperitoneal, intravenous, and
<br /> possibly other routes. Moderately toxic by ingestion and subcutaneous
<br /> routes. A severe eye and moderate skin irritant. Human systemic effects
<br /> by inhalation and ingestion: blood changes, increased body temperature.
<br /> Experimental teratogenic and reproductive effects. Human mutation data
<br /> reported. A narcotic. In industry, inhalation is the primary route of
<br /> chronic benzene poisoning. Poisoning by skin contact has been reported.
<br /> Recent (1987) research indicates that effects are seen at less than 1
<br /> ppm. Exposures needed to be reduced to 0.1 ppm before no toxic effects
<br /> were observed. Elimination is chiefly through the lungs. A common air
<br /> contaminant.
<br /> 9
<br /> Site Safety L Health Plan Rev./1.0
<br /> October 20, 1997
<br />
|